Coridon HSV-2 vaccine shows 100% efficacy

Brisbane, Australia-based biotech Coridon has developed a DNA vaccine for herpes simplex virus 2 that showed 100% efficacy in a preclinical trial. Thanks to financial backing from Allied Healthcare Group, Coridon hopes to push the vaccine into human trials in the next year. As a DNA vaccine, the HSV-2 vax can be used both for preventative and curative measures. Article

Suggested Articles

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

To eradicate SARS-CoV-2, we'll need a vaccine that's 70% effective—and 70% of the population will need to receive it, an FDA official says.

The U.K. government, fearing losing the supply race, agreed to buy 60 million doses of GSK-Sanofi's COVID-19 vaccine even before phase 1.